Amylyx Pharmaceuticals, Inc.
AMLX
$3.63
-$0.045-1.23%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -893.62% | -447.98% | -429.35% | -7,652.00% | 111.08% |
| Total Depreciation and Amortization | -46.84% | -26.82% | -25.98% | 54.41% | 65.38% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -27.02% | 439.51% | 83.34% | 2,462.53% | 64.55% |
| Change in Net Operating Assets | -1,815.03% | 68.89% | 59.95% | 101.43% | 113.65% |
| Cash from Operations | -535.45% | -704.22% | -873.38% | 90.36% | 127.27% |
| Capital Expenditure | 94.38% | -10,035.57% | 67.99% | 73.20% | 42.58% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 205.44% | 169.62% | -123.38% | -98.42% | 109.35% |
| Cash from Investing | 210.54% | 135.91% | -123.50% | -98.54% | 109.17% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -57.35% | -50.10% | -97.79% | -59.14% | -99.85% |
| Repurchase of Common Stock | 67.52% | -332.63% | 97.30% | 44.35% | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 100.00% |
| Cash from Financing | -52.17% | -91.00% | -98.05% | -87.40% | -99.90% |
| Foreign Exchange rate Adjustments | -321.52% | 276.12% | -116.67% | -246.67% | -53.25% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -84.10% | 97.83% | -171.74% | -99.33% | 177.29% |
